Stay updated on Safety of SNA-120 in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Safety of SNA-120 in Psoriasis Clinical Trial page.

Latest updates to the Safety of SNA-120 in Psoriasis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA new Revision: v3.5.0 was added and the previous Revision: v3.4.3 was removed.SummaryDifference0.0%

- Check16 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedAdded Revision: v3.4.2. Removed the notice about government funding and the earlier Revision: v3.4.1.SummaryDifference0.4%

- Check52 days agoChange DetectedNotice added: a government-funding lapse advisory appears on the page and the revision is updated to v3.4.1 (previously v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check59 days agoChange DetectedAdded a Show glossary option and updated QC-related text and revision numbers (Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0) with capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check73 days agoChange DetectedRevision notes show an addition of Revision: v3.3.4 and a deletion of Revision: v3.3.3.SummaryDifference0.0%

Stay in the know with updates to Safety of SNA-120 in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of SNA-120 in Psoriasis Clinical Trial page.